The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Open accessAbstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., "convalescent") plasma refers to plasma that is collected from individuals following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scale-up is brought underway to mobilize this critical resource.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Detection of SARS-CoV-2 in Different Types of Clinical Specimens
Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020) · JAMA · doi:10.1001/jama.2020.3786 · Cited by 5,028
Epidemiology of COVID-19 Among Children in China
Dong, Y., Mo, X., Hu, Y., Qi, X., Jiang, F., Jiang, Z., & Tong, S. (2020) · Pediatrics · doi:10.1542/peds.2020-0702 · Cited by 4,090
Early dynamics of transmission and control of COVID-19: a mathematical modelling study
Kucharski, A. J., Russell, T. W., Diamond, C., Liu, Y., Edmunds, J., Funk, S., Eggo, R. M., Sun, F., Jit, M., Munday, J. D., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30144-4 · Cited by 2,671
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S., Boundy, E., Bowen, V., Chow, N., Cohn, A., Dowling, N., Ellington, S., Gierke, R., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,277
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Mizumoto, K., Kagaya, K., Zarebski, A., & Chowell, G. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.10.2000180 · Cited by 2,276
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,960
Li, Z., Yi, Y., Luo, X., Xiong, N., Liu, Y., Li, S., Sun, R., Wang, Y., Hu, B., Chen, W., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25727 · Cited by 1,771
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
Guo, L., Ren, L., Yang, S., Xiao, M., Chang, D., Yang, F., Dela Cruz, C. S., Wang, Y., Wu, C., Xiao, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa310 · Cited by 1,587
Antibody-dependent enhancement of severe dengue disease in humans
Katzelnick, L. C., Gresh, L., Halloran, M. E., Mercado, J. C., Kuan, G., Gordon, A., Balmaseda, A., & Harris, E. (2017) · Science · doi:10.1126/science.aan6836 · Cited by 1,205
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P., Wong, K. C., Leung, C. B., & Cheng, G. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 958
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903
Self-citationHung, I. F., To, K. K., Lee, C.-K., Lee, K.-L., Chan, K., Yan, W.-W., Liu, R., Watt, C.-L., Chan, W.-M., Lai, K.-Y., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 678
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., Shi, Z., et al. (2020) · Journal of Virology · doi:10.1128/jvi.02015-19 · Cited by 662
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
Luke, T. C., Kilbane, E. M., Jackson, J. L., & Hoffman, S. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00139 · Cited by 636
Passive antibody therapy for infectious diseases
Casadevall, A., Dadachova, E., & Pirofski, L.-A. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro974 · Cited by 531
Self-citationBurke, R. M., Midgley, C. M., Dratch, A., Fenstersheib, M., Haupt, T., Holshue, M., Ghinai, I., Jarashow, M. C., Lo, J., McPherson, T. D., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6909e1 · Cited by 475
Is COVID-19 receiving ADE from other coronaviruses?
Tetro, J. A. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.02.006 · Cited by 434
Noninfectious Serious Hazards of Transfusion
Hendrickson, J. E., & Hillyer, C. D. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181930a6e · Cited by 419
Treatment with Convalescent Plasma for Influenza A (H5N1) Infection
Zhou, B., Zhong, N., & Guan, Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070359 · Cited by 406
Cao, W., Liu, X., Bai, T., Fan, H., Hong, K., Song, H., Han, Y., Lin, L., Ruan, L., & Li, T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa102 · Cited by 405
Secondary attack rate and superspreading events for SARS-CoV-2
Liu, Y., Eggo, R. M., & Kucharski, A. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30462-1 · Cited by 350 · cited 1×
“(47, 48); a high proportion of those who are infected will go on to severe disease, including death (~1%–4”
Ko, J.-H., Seok, H., Cho, S. Y., Ha, Y. E., Baek, J. Y., Kim, S. H., Kim, Y.-J., Park, J. K., Chung, C. R., Kang, E.-S., et al. (2018) · Antiviral Therapy · doi:10.3851/imp3243 · Cited by 323
Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases
Casadevall, A., & Scharff, M. D. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.150 · Cited by 318
Self-citationPrevention of transfusion-transmitted infections
Busch, M. P., Bloch, E. M., & Kleinman, S. (2019) · Blood · doi:10.1182/blood-2018-11-833996 · Cited by 294
Self-citationFc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281
Serum therapy revisited: animal models of infection and development of passive antibody therapy
Casadevall, A., & Scharff, M. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1695 · Cited by 251
Self-citationYeh, K.-M., Chiueh, T.-S., Siu, L. K., Lin, J.-C., Chan, P. K. S., Peng, M.-Y., Wan, H.-L., Chen, J.-H., Hu, B.-S., Perng, C.-L., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki346 · Cited by 247
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Arabi, Y. M., Hajeer, A. H., Luke, T., Raviprakash, K., Balkhy, H., Johani, S., Al-Dawood, A., Al-Qahtani, S., Al-Omari, A., Al-Hameed, F., et al. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2209.151164 · Cited by 244
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
Gunn, B. M., Yu, W.-H., Karim, M. M., Brannan, J. M., Herbert, A. S., Wec, A. Z., Halfmann, P. J., Fusco, M. L., Schendel, S. L., Gangavarapu, K., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.07.009 · Cited by 218
A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma.
Bobek, V., Kološtová, K., Pintérová, D., Kacprzak, G., Adamiak, J., Kołodziej, J., Boubelı́k, M., Kubecova, M., & Hoffman, R. M. (2010) · PubMed · Cited by 200
Estimating Risk for Death from Coronavirus Disease, China, January–February 2020
Mizumoto, K., & Chowell, G. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2606.200233 · Cited by 188
Comprehensive Analysis of HPV Expression in Laryngeal Squamous Cell Carcinoma
Sá, A. C. C., Gómez, M. M., Lima, I. F. N., et al. (2014) · Universidad de Chile · doi:10.1002/jmv · Cited by 178
Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations
Chang, L., Zhao, L., Gong, H., Wang, L., & Wang, L. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200839 · Cited by 177
Antibody-mediated regulation of cellular immunity and the inflammatory response
Casadevall, A., & Pirofski, L.-A. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00228-x · Cited by 168
Self-citationCasadevall, A. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0808.010516 · Cited by 165
Self-citationTreatment of severe acute respiratory syndrome with convalescent plasma.
Wong, V. W., Dai, D., Wu, A. K. L., & Sung, J. J. �. (2003) · PubMed · Cited by 142
Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone
Sahr, F., Ansumana, R., Massaquoi, T. A., Idriss, B. R., Sesay, F. R., Lamin, J. M., Baker, S., Nicol, S., Conton, B., Johnson, W. R., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.11.009 · Cited by 121
A serological survey on neutralizing antibody titer of SARS convalescent sera
Zhang, J.-S., Chen, J.-T., Liu, Y.-X., Zhang, Z.-S., Gao, H., Liu, Y., Wang, X., Ning, Y., Liu, Y.-F., Gao, Q., et al. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20431 · Cited by 93
Chun, S., Chung, C. R., Ha, Y. E., Han, T. H., Ki, C., Kang, E., Park, J. K., Peck, K. R., & Cho, D. (2016) · Annals of Laboratory Medicine · doi:10.3343/alm.2016.36.4.393 · Cited by 55
Disease-Enhancing Antibodies Improve the Efficacy of Bacterial Toxin-Neutralizing Antibodies
Chow, S.-K., Smith, C., MacCarthy, T., Pohl, M. A., Bergman, A., & Casadevall, A. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.03.001 · Cited by 28
Self-citation
Cited by
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
Viral targets for vaccines against COVID-19
Dai, L., & Gao, G. F. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 1,048
Crawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 776
COVID-19: Immunology and treatment options
Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108448 · Cited by 669
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Metadata
- Authors
- Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., Pekosz, A., Lau, B., Wesolowski, A., Katz, L., Shan, H., Auwaerter, P. G., Thomas, D., Sullivan, D. J., Paneth, N., Gehrie, E., Spitalnik, S., Hod, E. A., Pollack, L., Nicholson, W. T., Pirofski, L.-A., Bailey, J. A., & Tobian, A. A. R.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-06-01
- Volume
- 130
- Issue
- 6
- Pages
- 2757-2765
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3014853902
- Cited by
- 799
- References
- 45
- FWCI
- 22.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.